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Abstract
Equo ne credite, Teucri. Quidquid id
est, timeo Danaos et dona ferentes (Do not
trust the horse, Trojans! Whatever it is, I
fear the Greeks, even bringing gifts) said
Laocoön (Virgil, the Aeneid book). Cancer
stem cells (CSCs) are populations of cancer
cells that can be found in different cancer-
ous tissues and organs, and have properties
that are similar to normal stem cells. They
are thought to be chemo-resistant and radio-
resistant and are therefore responsible for
cancer recurrence and relapse encountered
in cancer patients following chemotherapy
and radiotherapy. Although significant
progress has been made to characterise
CSCs, it is becoming clear that the failure of
cancer therapies directed against certain
types of aggressive cancers is due to the
presence of these malignant cells. Cancer
therapies that will rely on a combination of
CSCs-targeted therapies, chemotherapy and
radiotherapy are more likely to succeed in
eradicating aggressive cancers and prevent
recurrence in treated patients.
Introduction: the Trojan horse
One of the most challenging aspects of
successful cancer therapies relates to the
fact that within cancerous tissues, different
populations of cancer cells exist and con-
tribute to the heterogeneous feature of
tumors and, consequently, offer different
potential target molecules for treatment.
However, there is an increasing body of evi-
dence that a small percentage of cancer
cells known as cancer stem cells (CSCs) or
cancer initiating cells have a profound
impact on the development of aggressive
life-threatening disease. CSCs are consid-
ered by many scientists to i) be the primary
drivers of cancer initiation by promoting the
transition from pre-malignant to malignant
tissue; ii) play a key role in invasion and
metastasis that are associated with cancer
progression; iii) be responsible for the dis-
ease recurrence in patients with cancer fol-
lowing chemotherapy or radiotherapy.
Since the first experimental identification of
CSCs in acute myeloid leukaemia cells,1
several studies have identified CSCs in
solid tumors including breast,2 brain,3
melanoma,4 prostate,5 ovarian,6 gastric,7
lung,8 and pancreatic9 cancers. Like their
normal stem cell counterparts, CSCs are
characterised by their capacity for self-
renewal and for the generation of differenti-
ated progenies. These processes are respon-
sible for driving tumorigenesis; and pro-
moting tumor growth and metastasis.10
Another important aspect that is associated
with CSCs, is the presence of oncogenic-
related mechanisms that allow CSCs to
resist cancer therapies and therefore con-
tributes to tumor aggressiveness.11,12 CSCs
can enter a dormancy state which limits the
effect of chemotherapeutic compounds that
target proliferating cells. They also express
several molecules such as the ATP-binding
cassette family of transporters (e.g.
ABCG2) that pump-out chemotherapeutic
compounds from cells. They have elevated
levels of ALDH1 (Aldehyde
Dehydrogenase) enzymatic activity. This
cytosolic enzyme oxidises aldehydes and
converts them into carboxylic acids provid-
ing CSCs with further chemoresistence.
CSCs also have a high DNA damage
response, which allows them to resist radio-
therapy- and chemotherapy-mediated dam-
age. Another mechanism relies on high
expression of the pro-survival BCL-2 pro-
tein family members that bind to the pro-
apoptotic proteins BCL2-associated-X-pro-
tein (BAX) and BCL-2 homologous antag-
onist killer (BAK) and impair their ability
to release apoptogenic proteins such as
cytochrome c from the mitochondria. To
prevent CSC-mediated chemoresitance and
recurrence in patients suffering from
aggressive cancers, it is essential to com-
bine traditional chemotherapy and radio-
therapy with efficient CSC-targeted thera-
pies.
Stem cells versus cancer stem
cells
To define cancer stem cells, it is essen-
tial to provide a definition of what are stem
cells. Stem cells are undifferentiated and
pluripotent cells that are capable of self-
renewal and of generating differentiated
cells. They are at the origin of all tissues and
organs within the body and, during adult-
hood, contribute to tissues homeostasis and
maintenance. In early embryogenesis,
embryonic stem cells (ESCs) that are found
in the inner cell mass give rise to the three
germ layers (ectoderm, mesoderm and
endoderm) that in turn, generate tissue-spe-
cific stem cells. These cells are at the origin
of somatic stem cells (SSCs) that play an
essential role in tissue regeneration follow-
ing cell death or organ damage. Although
SSCs possess stem cell properties, they are
only capable of generating tissue-specific
progenies. They can also be hierarchically
organised into a stem cell, progenitor cells
and mature cells (Figure 1). The progres-
sion from a stem cell to mature cells is tight-
ly regulated by tissue-specific environmen-
tal cues that act in a Start-Break fashion,
and depending on tissue requirement for
maintenance and regeneration. In cancer,
the process of transformation of healthy
cells into cancer cells is triggered by the
accumulation of genetic mutations affecting
key pathways that are involved in the con-
trol of cell proliferation, differentiation and
apoptosis. In a similar fashion, mutations
affecting somatic stem cells would result in
the generation of cancer stem cells (Figure
1). It is not unlikely that mutations that may
affect non-CSC could also generate CSCs-
like cells as a result of oncogenic acquisi-
tion of stem cell-like properties. In addition,
it has been shown that non-CSCs could con-
vert into CSCs through inflammatory stro-
ma that activates NFB signalling, which
enhances Wnt signalling and induces dedif-
ferentiation of non-CSCs with gain of
tumor-initiating capacity.13 Another aspect
to consider is the potential role of the
microenvironment in promoting the trans-
formation of normal stem cells into cancer
stem cells. Recent studies have implicated
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epigenetic alterations that are initiated by
signals from the tumor microenvironment
and which may exert oncogenic selection
on normal stem cells leading to a dysfunc-
tional emergence of CSCs.14 Although fur-
ther investigations are required to better
characterise CSCs, these malignant cells
seem to be generated from mutations or epi-
genetic alterations that affect normal stem
cells and cancer cells.
Cancer stem cells, tumor
microenvironment and cancer
progression
CSCs exhibit many of the characteris-
tics associated with cancer stem cells that
have undergone epithelial-mesenchymal
transition (EMT).15 The role of EMT in
tumor invasion and metastasis has been
well studied and it is now evident that this
event is initiated by contextual signals pres-
ent in the tumor microenvironment.
Epithelial cells are characterised by their
baso-apical polarity that is maintained by
cell-cell junctions including desmosomes,
adherens and gap junctions. When EMT is
engaged, epithelial cells lose their polarity
via junctions’ disassembly that is mediated
by the downregulation of epithelial gene
expression (such as E-Cadherin) and upreg-
ulation of mesenchymal gene expression
(such as Vimentin and N-Cadherin). This
process results in the generation of mes-
enchymal-like cells capable of migration,
invasion and metastasis. In cancer, EMT is
promoted by the tumor microenvironment,
where cellular constituents such as CAFs
(cancer associated fibroblasts), MDSCs
(myeloid-derived suppressor cells), soluble
growth factors and cytokines, and hypoxic
and acidic conditions, induce pro-EMT
intracellular signalling pathways (TGFb,
Wnt/b-catenin, NFkB and Notch). This
results in the transdifferentiation of carcino-
ma cells into mesenchymal cancer cells.
Interestingly, many of these signals are also
found associated with CSCs. As an exam-
ple, the activation of EMT by TGFb and the
transcriptional activators Snail1, Twist1 and
Zeb1 in normal epithelial cells results in the
acquisition of CSCs traits.16 Another exam-
ple is the Wnt/b-catenin pathway, which
plays an important role in the maintenance
of CSCs, is also a critical inducer of EMT in
carcinomas. Although the transformation of
epithelial cells into mesenchymal ones
necessitates EMT, this process may not be
the only cellular mechanism that is involved
in CSCs-associated invasion and metasta-
sis. CSC-generated hierarchy of stem-like
and differentiated tumor cells, also known
as tumor cell plasticity, can initiate metasta-
tic growth and is seen in late-stage cancers
and at metastatic sites.17 It is not impossible
that CSCs may generate progenies that lack
cell-cell adhesions and that are capable of
migration, invasion and metastasis. It will
be interesting to investigate if some tumor
circulating cells have characteristics that are
not associated with the mesenchymal phe-
notype. Finally, cancer cell autonomous
functions such as invadopodia formation,
paracrine factors as VEGF and Epidermal
growth factor (EGF) family members, pro-
teases as MMPs and cathepsins, and recruit-
ment of stromal components and immuno-
suppressive cells as TAMs can also promote
CSCs dissemination.18
Burning the Trojan horse: are
we there yet?
Although significant advances in defin-
ing markers that can identify CSCs in solid
tumors have been made, issues remain
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Figure 1. Potential cellular mechanisms involved in the generation of cancer stem cells (CSCs). A) Stem cells generate progenitor cells
that produce mature cells. Mutations in stem cells or their progenitor cells may result in the generation of CSCs or progenitor cancer
cells. Both types may have the capacity for self-renewal and for the generation of differentiated progenies. B) Mutations in mature cells
may initiate their dedifferentiation in CSCs-like cells. C) The tumor microenvironment could initiate epigenetic alterations in normal
stem cells inducing their transformation into CSCs.
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about their specificity for CSCs.19 For
example, although CD44 and CD133 have
been used as markers of CSCs, these mark-
ers are also expressed by multiple cell
types, including sub-populations of stromal
cells and interstitial cells such as immuno-
stimulatory cells. These observations raise
questions about their suitability as CSCs
markers and limit their potential use as tar-
gets for cancer therapies among scientists
and clinicians working in the field. Several
therapeutic approaches20 have been used to
target CSCs. First, antibodies targeting cell
surface markers that are widely expressed
by CSCs and play a role in cancer prolifer-
ation, survival, migration and invasion.
These include molecules such as the cell
surface glycoprotein prominin-1 (CD133),
the hyaluronic acid receptor CD44 or the
transmembrane protein receptor (CD47).
Second, targeting signalling cascades that
are involved in self-renewal and differentia-
tion and define stemness such as Notch,
Hedgehog or Wnt/-catenin pathways.
Third, manipulation of the expression of
miRNAs that are involved in the mainte-
nance of stemness and tumor progression
(e.g. miR-21, miR-34, miR-124). Fourth,
targeting ABC cassette transporters. These
molecules are abnormally expressed by
CSCs and are responsible for driving drug
efflux and therefore play an important role
in CSC-associated chemoresistence. Fifth,
inducing CSC differentiation using mole-
cules such as retinoic acid and histone
deacetylase inhibitors. Sixth, targeting the
CSC microenvironment. This relies on tar-
geting chemokines and their receptors (e.g.
CXCL12-CXCR4), or molecules such as
the vascular-endothelial growth factor
(VEGF). Seventh, induction of CSC apop-
tosis by activating cell death receptors (e.g.
TRAIL, CD95) or inhibiting survival path-
ways. Common limitations of these new
advances are: i) the molecules and path-
ways targeted are not specific to CSCs and
are found in healthy tissue and normal stem
cells, hence the higher toxicity encountered
using these therapies; ii) lack of thorough
understanding of cellular pathways regulat-
ing CSCs role in cancer initiation/progres-
sion, and their interactions with the
microenvironment (such as immune sys-
tem, angiogenesis, hypoxia). It is therefore
essential to identify CSC-specific targets
that are key to successful development of
therapies and that are based on robust and
reliable methods of identification. This step
is inseparable from a better understanding
of the CSC niche.
Conclusions
Although the existence of CSCs in mul-
tiple human tumors has been firmly estab-
lished, unique biomarkers that could be
used to identify CSCs for patient clinical
evaluation (diagnostic, prognostic and pre-
dictive), and that could also be used for tar-
geted therapies is still a major challenge for
scientists and clinicians working in this
exciting field. CSCs express many antigens
that are present in normal stem cells and in
other tissues of the body, and attempts that
aim at targeting them would result in
increased toxicity with potential and life-
threatening consequences for treated
patients. The identification of new biomark-
ers that are truly specific to CSCs will cer-
tainly lead to more efficient therapies. In
this regard, large scale analysis of tumor
samples from different patients and cohorts
using genomics, proteomics and data min-
ing approaches (Bioinformatics) could lead
to the identification of CSCs-specific genes
or antigens signatures that will open new
avenues for the development of CSCs tar-
geted therapies. Although in vivo studies
that rely on mice xenotransplantation from
patient isolated cancer cells have certainly
made significant advances for our under-
standing of cancer stem cell behavior, these
studies can only provide partial information
if identified biomarkers are not clinically
validated. Finally, it is an exciting time for
many scientists to be working in this chal-
lenging field of cancer research and
progress will certainly be made in the future
with significant impact on cancer therapy. 
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